Johnson & Johnson is expected to have steady sales but fall short on profits in its upcoming Q3 report.

JNJ · Johnson & Johnson

The AI's read

That points to pressure on profit without a sales surprise. The analyst also expects higher research costs and a larger profit reduction from acquired research in 2027. The higher sales estimate for Icotyde is a possible future benefit, but it does not erase the expected profit miss.